Author

C. Blanquart

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell-cell communication· 1

Frequent Co-Authors

C. Meiller· 2 shared D. JEAN· 2 shared A. Hariharan· 1 shared A. Krontira· 1 shared A. Marazioti· 1 shared A. S. Lamort· 1 shared B. Vrugt· 1 shared C. M. Hackl· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Meiller

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Heterogeneity of RNA editing in mesothelioma and how RNA editing enzyme ADAR2 affects mesothelioma cell growth, response to chemotherapy and tumor microenvironment

A. Hariharan, W. Qi, H. Rehrauer, L. Wu, M. Ronner, M. Wipplinger, J. Kresoja-Rakic, S. Sun, L. Oton-Gonzales, M. Sculco, V. Serre-Beinier, C. Meiller, C. Blanquart, J.-F. Fonteneau, B. Vrugt, , E. Felley-Bosco

This study examines RNA editing heterogeneity in mesothelioma and shows ADAR2's role in cell growth, chemotherapy response, and tumor microenvironment regulation.

bioRxiv · Jul 12, 2022Cancer Biology

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

S. Paternot, E. Raspe, C. Meiller, M. Tarabichi, J.-B. Assie, F. Libert, M. Remmelink, X. Bisteau, P. Pauwels, Y. Blum, N. Le Stang, S. Tabone-Eglinger, F. Galateau-Salle, C. Blanquart, J. P. Van Meerbeeck, , P. P. Roger

This study shows that CDK4 phosphorylation predicts sensitivity of malignant pleural mesothelioma to CDK4/6 inhibitors, with 80% of tumors expressing phosphorylated CDK4.

bioRxiv · Apr 11, 2022Cancer Biology

KRAS signalling in malignant pleural mesothelioma

A. Marazioti, A. Krontira, M. A. Pepe, M. Iliopoulou, D. E. Wagner, H. Papadaki, S. G. Antimisiaris, I. Psallidas, M. Spella, I. Lilis, I. Giopanou, M. Vreka, C. Blanquart, M. Gregoire, S. Deshayes, , G. T. Stathopoulos

This study identifies KRAS mutations as a significant driver in human malignant pleural mesothelioma and demonstrates their role in disease initiation and treatment response in mouse models.

bioRxiv · Oct 22, 2020 · PreprintPhysiology